REVONTO Drug Patent Profile
✉ Email this page to a colleague
When do Revonto patents expire, and when can generic versions of Revonto launch?
Revonto is a drug marketed by Uswm and is included in one NDA.
The generic ingredient in REVONTO is dantrolene sodium. There are five drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the dantrolene sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Revonto
A generic version of REVONTO was approved as dantrolene sodium by IMPAX LABS on March 1st, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REVONTO?
- What are the global sales for REVONTO?
- What is Average Wholesale Price for REVONTO?
Summary for REVONTO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 69 |
| Drug Prices: | Drug price information for REVONTO |
| DailyMed Link: | REVONTO at DailyMed |
Pharmacology for REVONTO
| Drug Class | Skeletal Muscle Relaxant |
| Physiological Effect | Decreased Striated Muscle Contraction Decreased Striated Muscle Tone |
US Patents and Regulatory Information for REVONTO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Uswm | REVONTO | dantrolene sodium | INJECTABLE;INJECTION | 078378-001 | Jul 24, 2007 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
